Researchers found people stopped weight loss drugs sooner if they were younger, poorer, or male. Millions worldwide now take medications such as Ozempic and Wegovy. Yet over half quit within a year, according to new Danish research.
High Dropout Rates Raise Concerns
The study examined data from 77,000 patients using anti-obesity drugs without diabetes. Results showed 52 percent stopped within 12 months. Eighteen percent quit by three months, 31 percent by six months, and 42 percent by nine months. Researchers said the dropout rates undermine the drugs’ effectiveness. “The medications must be taken long term,” explained Aarhus University professor Reimar W. Thomsen. He added that stopping treatment cancels the appetite-controlling benefits.
Demographic and Economic Barriers
Younger adults, men, and residents in low-income areas were more likely to abandon treatment. Adults under 30 faced a 48 percent higher risk of quitting compared with those aged 45 to 59. People in poorer neighborhoods were 14 percent more likely to stop treatment than wealthier peers. Researchers suggested cost contributes to the problem. In Denmark, a month’s supply of Ozempic can reach €313 without government coverage, while in Germany it costs about €120.
Side Effects and Health Conditions Play a Role
Patients with chronic illnesses or previous use of psychiatric or gastrointestinal medications also quit more often. Researchers believe side effects such as nausea and vomiting pushed many to stop. These findings highlight the complex factors affecting long-term adherence.
Public Health Implications
Researchers warned that ending treatment often leads to regained weight. That possibility fuels debate about whether patients must take the drugs indefinitely. Thomsen stressed that more must be done to support patients, especially since GLP-1 drugs reduce risks of heart disease, cancer, and addiction.
He emphasized Europe’s urgent need for effective support strategies. “Over half of European adults live with overweight or obesity,” Thomsen stated. “Understanding who benefits most from sustained treatment is vital to improve health outcomes and quality of life.”
Global Relevance
The findings, set for presentation at the European Association for the Study of Diabetes in Vienna, underscore widespread challenges. With obesity and related health risks climbing, ensuring access and adherence could shape public health for decades.
